Endo International has made a competing offer of between $170 and $175 per share for Salix Pharmaceuticals, the Wall Street Journal reported, citing sources.
Canada’s Valeant Pharmaceuticals International (VRX) agreed to buy bowel drug maker Salix in late February for about$10 billion, or $158 per share. Endo sent a private offer letter to Salix’s board on Wednesday, the Journal reported.
Shares of Salix Pharma rose 7% to $168.50 on the Journal’s report. Valeant, meanwhile, is down 4%, noted Street Insider.
Valeant spokeswoman Laurie Little said the company does not comment on market rumors. Salix and Endo were not immediately available for comment.
Fortune contributed to this report.
Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.
